Women are suffering as a result of gender bias that affects the design, testing, clinical trials, regulatory approval, and clinical use of implantable devices, according to recent research.
Dr Katrina Hutchinson, a Postdoctoral Research Fellow in the philosophy department at Macquarie University, suggests that regulators like the Therapeutic Goods Administration could influence device design by requiring data on the safety and performance of all new and modified devices in both women and men.
Her article below was first published at The Conversation.
Katrina Hutchinson writes:
The past year has seen wide concern about the safety of medical implants. Some of the worst scandals have involved devices for women, such as textured breast implants with links to cancer, and transvaginal mesh implants, which were the subject of a senate inquiry.
But women are harmed not only by “women’s devices” such as breast implants and vaginal mesh. Women are also more likely to be harmed by apparently gender-neutral devices, like joint replacements and heart implants.
In recently published research, I explored the reasons for this. I found gender biases at all stages of design and use of medical implants.
Proposed changes to how devices are regulated, such as introducing a national register of all implants, will make it quicker to identify dodgy devices. But this will not address gender bias in how devices are designed and used.
Bias starts with design, then lab testing
Bias continues with clinical trials
Some medical device companies have exploited regulatory loopholes to get devices to market in the UK without clinical trials. Even when trials take place, women are not always included. Or researchers do not analyse the data for gender differences.
Regulators such as the Food and Drug Administration (FDA) in the United States and Australia’s Therapeutic Goods Administration (TGA) often approve devices without data split by gender on how well devices perform or how safe they are.
Then there’s the doctor-patient relationship
The gender of the doctor and patient can make a difference to what women learn about their implant. The very low numbers of women in surgery mean female patients often see male surgeons. And there is some evidence male doctors tend to treat female patients in a more paternalistic and less patient-centred way.
Then there’s the issue of whether surgeons raise important safety issues with their female patients. For example, some surgeons feel uncomfortable discussing whether it’s safe to have sex after a hip implant, especially with female patients. This is important as some sexual positions are safer than others.
Let’s look at one example, a hip implant
The DePuy ASR (articular surface replacement) hip implant caused serious complications for patients around the world, including Australia, such as inflammation, painful growths, dislocations and metal toxicity.
In the case of hip implants, the same models are available for women and men, implying these devices are gender neutral. Most models come in a range of sizes, with some having better outcomes for women. But women are not small men, and there are gender differences in basic activities involving the hip, such as walking.
When women stand up from sitting or have sex, the fragile edges of their hip sockets tend to bear greater loads than men’s. This “edge loading” increases the risk hip implants will wear down and release dangerous metal particles.
These differences would not matter if lab tests showed equal safety of hip implants for men and women. However, evidence is not collected on this. In fact, international standards for lab tests that measure rates of wear in hip implants ignore gender differences, and only test normal walking rather than more stressful activities, such as running or having sex.
The FDA, TGA and other regulators often approve new hip implants based on their similarity to already approved models. This happened with the ASR hip implant. Regulators did not need new data, let alone evidence the hip was equally safe for women and men.
It’s a concern internationally
Internationally, there is increasing concern about the regulation and safety of medical implants. An international group of journalists released a damning report late last year. The FDA’s 510(k) process, which approves new devices based on their similarity to existing ones, allows approval of some high-risk implants without additional evidence.
The situation is no better in Europe, where commercial agencies do the approvals. This system has been criticised for approving devices without good data and for lacking transparency when it comes to implant recalls.
The FDA has taken some steps to address gender bias, issuing guidance for companies to provide data on their devices in women and men. However, this is not binding. A study of devices approved after its introduction found only 17% included data analysis by sex.
How could we improve things?
In Australia, scandals with implants have led to calls for bans and registries. These are good ideas, but will not prompt new devices to be designed with women in mind, nor improve patient communication.
Surgeons need to raise topics important for their patients to know about surgery, however uncomfortable it makes them feel. Current efforts to improve the culture of surgery, and to attract trainees who better reflect the communities they serve may help. But there is a long way to go.
Regulators like the TGA and FDA can influence device design by requiring data on the safety and performance of all new (and modified) devices in both women and men. The FDA experience shows these requirements must be binding if they are to work.
This article was first published at The Conversation.